Compare · GEV vs PBAX
GEV vs PBAX
Side-by-side comparison of GE Vernova Inc. (GEV) and Phoenix Biotech Acquisition Corp. (PBAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- GEV operates in Technology, while PBAX operates in Industrials - the two are in different parts of the market.
- GEV carries a market cap of $216.64B.
- GEV has hit the wire 8 times in the past 4 weeks while PBAX has been quiet.
- GEV has more recent analyst coverage (25 ratings vs 0 for PBAX).
- Company
- GE Vernova Inc.
- Phoenix Biotech Acquisition Corp.
- Price
- -
- -
- Market cap
- $216.64B
- -
- 1M return
- -13.09%
- -
- 1Y return
- +46.58%
- -
- Industry
- Consumer Electronics/Appliances
- Consumer Electronics/Appliances
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- 2021
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 0
PBAX
Phoenix Biotech Acquisition Corp.
Phoenix Biotech Acquisition Corp. intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization, or similar business combination. It focuses on pursuing opportunities in the life sciences sector. The company was incorporated in 2021 and is based in Oakland, California.
Latest GEV
- Data Center Power Suppliers Post Backlog and Guidance Updates Alongside a Fuel Cell Deal
- GE Vernova Continues Wind Energy Expansion in Germany With New Order From Stadtwerke Heidenheim AG
- Amendment: SEC Form SCHEDULE 13G/A filed by GE Vernova Inc.
- GE Vernova upgraded by HSBC Securities with a new price target
- SEC Form 10-Q filed by GE Vernova Inc.
- SEC Form 8-K filed by GE Vernova Inc.
- GE Vernova to Acquire Trench Group
- Just 7% of the Uranium Delivered to U.S. Reactors Last Year Was U.S.-Origin. The Reactor Pipeline Is Still Moving.
- GE Vernova Declares Fourth Quarter 2026 Dividend
- US Utilities Plan 24 GW of New Battery Storage in 2026 as Interconnection Waits Stretch
Latest PBAX
- Phoenix Biotech Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Phoenix Biotech Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Change in Shell Company Status, Financial Statements and Exhibits, Leadership Update, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year (Amendment)
- New insider Corey Daniel claimed ownership of 671,470 shares (SEC Form 3) (Amendment)
- SEC Form D filed by Phoenix Biotech Acquisition Corp.
- SEC Form SC 13G/A filed by Phoenix Biotech Acquisition Corp. (Amendment)
- SEC Form 4 filed by Laporte Kathleen (Amendment)
- Atwood Brian G acquired 248,735 shares (SEC Form 4) (Amendment)
- SEC Form SC 13D/A filed by Phoenix Biotech Acquisition Corp. (Amendment)
- Loewy Caroline M acquired 5,828 shares (SEC Form 4)
- Kosacz Barbara acquired 5,828 shares (SEC Form 4)